Results 1 to 10 of about 2,816 (233)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals

Pharmaceutics, 2023
Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (177Lu) based radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine and oncology, allowing for personalized medicine.
Elise Levigoureux, Cédric Desmonts, Jonathan Vigne   +2 more
exaly   +5 more sources

Lutetium-177-PSMA-617: A Vision of the Future [PDF]

Cancer Biology & Therapy, 2022
In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[177Lu]Lu-PSMA-617 in post ...
Elias Chandran, William D. Figg, Ravi Madan   +2 more
doaj   +3 more sources

Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals [PDF]

EJNMMI Physics, 2018
Background This inter-comparison exercise was performed to demonstrate the variability of quantitative SPECT/CT imaging for lutetium-177 (177Lu) in current clinical practice.
Jill Wevrett, Andrew Fenwick, James Scuffham, Lena Johansson, Jonathan Gear, Susanne Schlögl, Marcel Segbers, Katarina Sjögreen-Gleisner, Pavel Solný, Michael Lassmann, Jill Tipping, Andrew Nisbet   +11 more
doaj   +8 more sources

Time toxicity of lutetium 177 in gastroenteropancreatic neuroendocrine tumours

Endocrine Oncology
Objectives: We aim to investigate the time toxicity of patients with gastroenteropancreatic neuroendocrine tumours treated with Lutetium-177 Dotatate in a single institution. Design: This is a retrospective cohort study.
Marcos Daniel Bortz, Andres Rodriguez, Maria Romina Luca, Federico Waisberg, Diego Enrico, Berenice Freile, Greta Catani, Federico Esteso, Martina Musumeci, Eliana Vazquez, Matías Chacón, Juan Manuel O’Connor, Silvina Racioppi   +12 more
doaj   +3 more sources

A Review of Prostate Cancer and the Effect of Lutetium Radiopharmaceutical [PDF]

Translational Research in Urology, 2023
Introduction: Prostate cancer is a type of disease in which malignant cells originate from prostate tissue and multiply irregularly and increasingly, leading to an increase in volume in each of the cellular components of the prostate gland.  Methods: The
Akram Amani, Bentolhoda Rashidi
doaj   +1 more source

Simultaneous Visualization of ¹⁶¹Tb- and ¹⁷⁷Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging

Pharmaceutics, 2021
The decay of terbium-161 results in the emission of β¯-particles as well as conversion and Auger electrons, which makes terbium-161 interesting for therapeutic purposes.
Francesca Borgna, Patrick Barritt, Pascal V. Grundler, Zeynep Talip, Susan Cohrs, Jan Rijn Zeevaart, Ulli Köster, Roger Schibli, Nicholas P. van der Meulen, Cristina Müller   +9 more
doaj   +1 more source

Repurposed Effect of ¹⁷⁷Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma

Current Oncology, 2022
Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium 177Lu-DOTATATE is a radiolabeled somatostatin analogue
Mohamad K. Elajami, Lorena P. Burton, Hisham F. Bahmad, Gerard Chaaya, Michael Schwartz   +4 more
doaj   +1 more source

Lutetium Lu-177 Dotatate Flare Reaction

Advances in Radiation Oncology, 2021
Purpose: Lutetium Lu-177 dotatate is the first peptide receptor radionuclide therapy approved by the US Food and Drug Administration. Well-designed studies in Europe have shown dramatic effectiveness in improving progression-free survival in patients ...
Andrew L. Salner, MD, Bette Blankenship, MS, Hayley Dunnack, BSN, RN, OCN, Christopher Niemann, PharmD, Helaine Bertsch, MD   +4 more
doaj   +1 more source

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2023
Objective(s): This study aimed to evaluate the therapeutic outcomes of 177Lutetium (177Lu)-PSMA-617 in metastatic castrate-resistant prostate cancer (mCRPC) patients, based on post-treatment imaging findings.
Seyed Ali Mirshahvalad, Saeed Farzaneh Far, Mehrshad Abbasi   +2 more
doaj   +1 more source

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer

Frontiers in Oncology, 2023
BackgroundLutetium-177 [177Lu]-PSMA-617 is a targeted radioligand that binds to prostate-specific membrane antigen (PSMA) and delivers radiation to metastatic prostate cancer.
Mathieu Gaudreault, Mathieu Gaudreault, David Chang, David Chang, Nicholas Hardcastle, Nicholas Hardcastle, Nicholas Hardcastle, Price Jackson, Price Jackson, Tomas Kron, Tomas Kron, Tomas Kron, Michael S. Hofman, Michael S. Hofman, Shankar Siva, Shankar Siva   +15 more
doaj   +1 more source